Treatment of interferon-α for chronic hepatitis C

Bibliography

• CHOO QL, KUO G, WEINER AJ, OVERBY LR, BRADLEY DW, HOUGHTON M: Isolation of a cDNA clone derived from a blood-bone non-A, non-B viral hepatitis genome. Science (1989) 244:359-362.
   PubMed Web of Science ®Google Scholar
• KUO G, CHOO QL, ALTER HJ et al.: An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science (1989) 244:362-364.
   PubMed Web of Science ®Google Scholar
• PERZ JF, FARRINGTON LA, PECORARO C, HUTIN YJ, ARMSTRONG GL: Estimated global prevalence of hepatitis C virus infection. 42nd Annual Meeting of the Infectious Disease Society of America, Boston, MA, USA (2004).
   Google Scholar
• MATSUMURA H, MORIYAMA M, GOTO I, TANAKA N, OHKUBO H, ARAKAWA Y: Natural course of progression of liver fibrosis in patients with chronic liver disease type C in Japan – a study of 527 patients at one establishment in Japan. J. Viral Hepat. (2000) 7:268-275.
   PubMedGoogle Scholar
• POYNARD T, BEDOSSA P, OPOLON P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet (1997) 349:825-832.
   PubMed Web of Science ®Google Scholar
• SHIRATORI Y, IMAZEKI F, MORIYAMA M et al.: Histological improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med. (2000) 132:517-524.
   PubMed Web of Science ®Google Scholar
• DESMET VJ, GERBER M, HOOFNAGLE JH, MANNS M, SCHEUER PJ: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology (1994) 19:1513-1520.
   PubMed Web of Science ®Google Scholar
• YOSHIDA H, SHIRATORI Y, MORIYAMA M et al.: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann. Intern. Med. (1999) 131:174-181.
   PubMed Web of Science ®Google Scholar
• NISHIGUCHI S, KUROKI T, NAKATANI S et al.: Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet (1995) 346:1051-1055.
   PubMed Web of Science ®Google Scholar
• IMAZEKI F, YOKOSUKA O, FUKAI K et al.: Lower incidence of hepatic failure than hepatocellular carcinoma in Japanese patients with chronic hepatitis C. Liver Int. (2005) 25(4):772-778.
   PubMedGoogle Scholar
• IKAI I, ARII S, ICHIDA T et al.: Report of the 16th follow-up survey of primary liver cancer. Hepatol. Res. (2005). In press.
   Google Scholar
• OMATA M, TATEISHI R, YOSHIDA H, SHIINA S: Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology (2004) 127(5 Suppl. 1):S159-S166.
   PubMed Web of Science ®Google Scholar
• HOOFNAGLE JH, MULLEN KD, JONES B et al.: Treatment of chronic non-A, non-B hepatitis with recombinant human α interferon. A preliminary report. N. Engl. J. Med. (1986) 615:1575-1578.
   Google Scholar
• ZEUZEM S, HERRMANN E, LEE JH et al.: Viral kinetics in patients with chronic hepatitis C treated with standard or PEG-interferon α2a. Gastroenterology (2001) 120:1438-1447.
   PubMed Web of Science ®Google Scholar
• MCHUTCHISON JG, GORDON SC, SCHIFF ER et al.: Interferon α2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. (1998) 339:1485-1492.
   PubMed Web of Science ®Google Scholar
• MONDARSH SP, MA Y, AGLIONE A et al.: Positional isomers of monopegylated interferon α2a: isolation, characterization, and biological activity. Anal. Biochem. (1997) 247:434-440.
   PubMedGoogle Scholar
• GLUE P, ROUZIER-PANIS R, RAFFANE C et al.: A dose-ranging study of pegylated interferon α2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology (2000) 32:647-653.
   PubMed Web of Science ®Google Scholar
• REDDY KR, WRIGHT TL, POCKROS PJ et al.: Efficacy and safety of pegylated (40-kd) interferon α2a compared with interferon α2a in noncirrhotic patients with chronic hepatitis C. Hepatology (2001) 33:433-438.
   PubMed Web of Science ®Google Scholar
• MANNS MP, MCHUTCHISON JG, GORDON SC et al.: PEG-interferon α2b plus ribavirin compared with interferon α2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 358:958-965.
   PubMed Web of Science ®Google Scholar
• ZEUZEM S, FEINMAN SV, RASENACK J et al.: PEG-interferon α2a in patients with chronic hepatitis C. N. Engl. J. Med. (2000) 343:1666-1672.
   PubMed Web of Science ®Google Scholar
• FRIDE MW, SHIFFMAN ML, REDDY KR et al.: PEG-interferon α2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. (2002) 347:975-982.
   PubMedGoogle Scholar
• SHIFFMAN ML, DI BISCEGLIE AM, LINDSAY KL et al.: Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group. PEG-interferon α2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 126:1015-1023.
   PubMedGoogle Scholar
• DAVIS GL, WONG JB, MCHUTCHISON JG, MANNS MP, HARVEY J, ALBRECHT J: Early virologic response to treatment with PEG-interferon-α2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 38:645-652.
   PubMedGoogle Scholar
• MCHUTCHISON JG, MANNS M, PATEL K et al.: International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 123:1061-1069.
   PubMedGoogle Scholar
• FRIED MW: Side effects of therapy of hepatitis C and their management. Hepatology (2002) 36(5 Suppl. 1):S237-S244.
   Google Scholar
• GUPTA SK, GLUE P, JACOBS S, BELLE D, AFFRIME M: Single-dose pharmacokinetics and tolerability of pegylated interferon-α2b in young and elderly healthy subjects. Br. J. Clin. Pharmacol. (2003) 56:131-134.
   PubMedGoogle Scholar
• SCHAEFER M, SCHMIDT F, FOLWACZNY C et al.: Adherence and mental side effects during hepatitis C treatment with interferon-α and ribavirin in psychiatric risk groups. Hepatology (2003) 37:443-451.
   PubMedGoogle Scholar
• RAISON CL, BORISOV AS, BROADWELL SD et al.: Depression during pegylated interferon-α plus ribavirin therapy: prevalence and prediction. J. Clin. Psychiatry (2005) 66:41-48.
   PubMedGoogle Scholar
• SHEPARD CW, FINELLI L, ALTER MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. (2005) 5(9):558-567.
   PubMedGoogle Scholar
• YOSHIZAWA H, TANAKA J, MIYAKAWA Y: National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Intervirology (2006) 49:7-17.
   PubMedGoogle Scholar
• HASAN F, ASKER H, AL-KHALDI J et al.: PEG-interferon α2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am. J. Gastroenterol. (2004) 99(9):1733-1737.
   PubMedGoogle Scholar
• GORDON SC, BAYATI N, SILVERMAN AL: Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology (1998) 28:562-567.
   PubMedGoogle Scholar
• DIBISCEGLIE AM, MARTIN P, KASSIANIDES C et al.: Recombinant interferon α therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. (1989) 321:1506-1510.
   PubMedGoogle Scholar
• DAVIS GL, BALART LA, SCHIFF ER et al.: Treatment of chronic hepatitis C with recombimant interferon-α. A multicenter randomized controlled study. N. Engl. J. Med. (1989) 321:1501-1506.
   PubMedGoogle Scholar
• POYNARD T, LEROY V, COHARD M et al.: Meta-analysis of interferon randomized trial in the treatment of viral hepatitis C: effect of dose and duration. Hepatology (1996) 24:778-789.
   PubMedGoogle Scholar
• ARASE Y, SUZUKI F, TSUBOTA A et al.: Sustained negative foe HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load. Intervirology (2004) 47:19-25.
   PubMedGoogle Scholar
• IINO S, ICHIDA F, SAKUMA A, SUZUKI H, Study group for chronic hepatitis C (OPC-18). Randomized clinical trial with natural interferon-α monotherapy for 24 or 48 weeks on patients with chronic hepatitis C having genotype 1b infection in high viral titers. Heptol. Res. (2002) 24:338-345.
   PubMedGoogle Scholar
• SUZUKI H, TANGO T: A multicenter, randomized, controlled clinical trial of interferon α con-1 in comparison with lymphoblastoid interferon-α in patients with high-titer chronic hepatitis C virus infection. Heptol. Res. (2002) 22:1-12.
   PubMedGoogle Scholar
• POYNARD T, MARCELLIN P, LEE SS et al.: Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet (1998) 352:1426-1432.
   PubMedGoogle Scholar
• VROLIJK JM, BEKKERING FC, BROUWER JT, HANSEN BE, SCHALM SW: High sustained virological response in chronic hepatitis C by combining induction and prolonged maintenance therapy. J. Viral Hepat. (2003) 10:205-209.
   PubMedGoogle Scholar
• HEATHCOAT EJ, SHIFFMAN ML, COOKSLEY GE et al.: PEG-interferon α2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. (2000) 343:1673-1680.
   PubMedGoogle Scholar
• FOSTER GR: Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus. Expert Opin. Pharmacother. (2003) 4(5):685-691.
   PubMedGoogle Scholar
• HADZIYANNIS SJ, PAPATHEODORIDIS GV: Peginterferon-α2a (40 kDa) for chronic hepatitis C. Expert Opin. Pharmacother. (2003) 4(4):541-551.
   PubMedGoogle Scholar
• PATEL K, MCHUTCHISON J: Peginterferon α2b: a new approach to improving response in hepatitis C patients. Expert Opin. Pharmacother. (2001) 2(8):1307-1315.
   PubMedGoogle Scholar
• LAU JY, TAM RC, LIANG TJ, HONG Z: Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology (2002) 35:1002-1009.
   PubMedGoogle Scholar
• THOMAS HC, TOROK ME, FORTON DM, TAYLOR-ROBINSON SD: possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J. Hepatol. (1999) 31(Suppl. 1):152-159.
   PubMedGoogle Scholar
• HULTGREN C, MILICH DR, WEILAND O, SALLBERG M: The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J. Gen. Virol. (1998) 79( Pt 10):2381-2391.
   PubMedGoogle Scholar
• PFEIFFER JK, KIRKEGAARD K: Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J. Virol. (2005) 79:2346-2355.
   PubMedGoogle Scholar
• KANDA T, YOKOSUKA O, IMAZEKI F et al.: Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. J. Viral Hepat. (2004) 11:479-487.
   PubMedGoogle Scholar
• CROTTY S, MAAG D, ARNOLD JJ et al.: The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. (2000) 6:1375-1379.
   PubMedGoogle Scholar
• ALMASIO PL: Weight-based dosing: which impact on efficacy and safety of therapy? Dig. Liver Dis. (2004) 36(Suppl. 3):S349-S353.
   Google Scholar
• ROSS C, HANSEN MB, SCHYBERG T, BERG K: Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-α 2b and human IFN-γ in healthy blood donors. Clin. Exp. Immunol. (1990) 82:57-62.
   PubMedGoogle Scholar
• KIMURA K: A cooperative Phase I – II study of HLBI in patients with malignant tumors. Gan To Kagaku Ryoho. (1984) 11:1324-1331.
   PubMedGoogle Scholar
• KASAHARA A, HAYASHI N, HIRAMATU N et al.: Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology (1995) 21:291-297.
   PubMedGoogle Scholar
• LINDSAY KL, TREPO C, HEINTGES T et al.: Hepatitis Interventional Therapy Group. A randomized, double-blind trial comparing pegylated interferon α2b to interferon α2b as initial treatment for chronic hepatitis C. Hepatology (2001) 34:395-403.
   PubMedGoogle Scholar
• FATTOVICH G, ZAGNI I, RIBERO ML et al.: A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone. J. Viral Hepat. (2004) 11:543-551.
   PubMedGoogle Scholar
• OKANOUE T, SAKAMOTO S, ITO Y et al.: Side effect of high-dose interferon therapy for chronic hepatitis C. J. Heptol. (1996) 25:283-291.
   PubMedGoogle Scholar
• KUMADA T, TOYODA H, HONDA T et al.: Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan. Intervirology (2006) 49:112-118.
   PubMedGoogle Scholar
• CHANDER G, SULKOWSKI MS, JENCKES MW et al.: Treatment of chronic hepatitis C: a systematic review. Hepatology (2002) 36(5 Suppl. 1):S135-S144.
   PubMedGoogle Scholar
• ONO E, SHIRATORI Y, OKUDAIRA T et al.: Platelet count reflects stage of chronic hepatitis C. Hepatol. Res. (1999) 15:192-200.
   Google Scholar
• MORIYAMA M, MATSUMURA H, AOKI H et al.: Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy. Intervirology (2003) 46:296-307.
   PubMedGoogle Scholar
• POHL A, BEHLING C, OLIVER D, KILANI M, MONSON P, HASSANEIN T: Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am. J. Gastroenterol. (2001) 96:3142-3146.
   PubMedGoogle Scholar
• BRUNO R, SACCHI P, PUOTI M, SORIANO V, FILICE G: HCV chronic hepatitis in patients with HIV: clinical management issues. Am. J. Gastroenterol. (2002) 97:1598-606.
   PubMedGoogle Scholar
• MAIDA I, SORIANO V, RAMOS B, RIOS P, GONZALEZ-LAHOZ J, NUNEZ M: Characteristics and prospects for hepatitis C therapy of an HIV-HCV coinfected population followed at a reference HIV center. HIV Clin. Trials (2005) 6:329-336.
   PubMed Web of Science ®Google Scholar
• ARTAN R, AKCAM M, YILMAZ A, KOCACIK D: Interferon α monotherapy for chronic hepatitis C viral infection in thalassemics and hemodialysis patients. J. Chemother. (2005) 17:651-655.
   PubMed Web of Science ®Google Scholar
• BUTENSKY E, PAKBAZ Z, FOOTE D, WALTERS MC, VICHINSKY EP, HARMATZ P: Treatment of hepatitis C virus infection in thalassemia. Ann. NY Acad. Sci. (2005) 1054:290-299.
   PubMedGoogle Scholar
• MORIYAMA M, MATSUMURA H, AOKI H et al.: Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy. Liver Int. (2005) 25:85-90.
   PubMedGoogle Scholar
• ARASE Y, IKEDA K, TSUBOTA A et al.: Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection. Intervirology (2004) 47:355-361.
   PubMedGoogle Scholar
• SAITO Y, SAITO H, TADA S et al.: Effect of long-term interferon therapy for refractory chronic hepatitis C: preventive effect on hepatocarcinogenesis. Hepatogastroenterology (2005) 52(65):1491-1496.
   PubMedGoogle Scholar
• NOMURA H, TANIMOTO H, SOU S et al.: Pilot study of prolonged interferon-α retreatment in chronic hepatitis C patients with genotype 1b. Hepatol. Res. (2003) 27(4):266-271.
   PubMedGoogle Scholar
• KUMAR R, KUMAR S, SHARMA BC, SINGH J, SARIN SK: Antiviral therapy in advanced chronic liver disease due to hepatitis C virus infection: pilot study. J. Gastroenterol. Hepatol. (2005) 20:527-535.
   PubMedGoogle Scholar
• EVERSON GT: Treatment of hepatitis C in the patients with decompensated cirrhosis. Clin. Gastroenterol. Hepatol. (2005) 3(10 Suppl. 2):S106-S112.
   Google Scholar
• CAMMA C, LICATA A, CABIBBO G, LATTERI F, CRAXI A: Treatment of hepatitis C: critical appraisal of evidence. Expert Opin. Pharmacother. (2005) 6(3):399-408.
   PubMed Web of Science ®Google Scholar
• IZUMI N, YASUHIRO A, KUROSAKI M et al.: Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. Is it possible to reduce the incidence by ribanirin and IFN combination therapy? Intervirology (2005) 48:59-63.
   PubMedGoogle Scholar
• AZZAROLI F, ACCOGLI E, NIGRO G et al.: Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. World J. Gastroenterol. (2004) 10:3099-3102.
   PubMed Web of Science ®Google Scholar
• UCHIDA T: Small hepatocellular carcinoma: its relationship to multistep hepatocarcinogenesis. Pathol. Int. (1995) 45:175-184.
   PubMedGoogle Scholar
• UENO Y, MORIYAMA M, UCHIDA T, ARAKAWA Y: Irregular regeneration of hepatocytes: an important factor of hepatocarcinogenesis in liver diseases. Hepatology (2001) 33:357-362.
   PubMedGoogle Scholar
• KUBO S, NISHIGUCHI S, HIROHASHI K et al.: Effects of long-term postoperative interferon-α therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann. Intern. Med. (2001) 134(10):963-967.
   PubMedGoogle Scholar
• SHIRATORI Y, SHIINA S, TERATANI T et al.: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann. Intern. Med. (2003) 138:299-306.
   PubMedGoogle Scholar
• PATT YZ, HASSAN MM, LOZANO RD et al.: Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Α2b for treatment of hepatocellular carcinoma. J. Clin. Oncol. (2003) 21:421-427.
   PubMedGoogle Scholar
• TSUDA N, YUKI N, MOCHIZUKI K et al.: Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J. Med. Virol. (2004) 74:406-413.
   PubMedGoogle Scholar
• MAKIYAMA A, ITOH Y, KASAHARA A et al.: Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer (2004) 101:1616-1622.
   PubMedGoogle Scholar
• CRIPPEN JS, MCCASHLAND T, TERRAUL N et al.: A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus infected patients awaiting liver transplantation. Liver Transpl. (2002) 8:350-355.
   PubMedGoogle Scholar
• WILLIAMS SJ, FARRELL GC: Inhibition of antipyrine metabolism by interferon. J. Clin. Pharmacol. (1986) 22:610.
   Google Scholar